Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's slow drug approvals, which can take as long as two years, are expected to speed up considerably in the Chinese Year of the Rabbit. China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations
You may also be interested in...
China Drug Approvals Up 26%, Mostly Due To Generics
China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals
China Drug Approvals Up 26%, Mostly Due To Generics
China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals
Reforms In China's Center For Drug Evaluation Designed To Boost Innovation - DIA China Conference
BEIJING - Ongoing reforms in China's drug review body are attracting the attention of the pharma industry, which is hoping the changes will result in a faster drug review process. During the third annual DIA China meeting in Beijing, officials from China's Center for Drug Evaluation unveiled more details of the reform and reaffirmed that the ultimate goals are to improve quality and drive efficiency of drug reviews